Zolpidem 12.5 9 tablets ingestion
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a clinical summary for Zolpidem 12.5 mg × 9 tablets (total 112.5 mg) ingestion:
Zolpidem Overdose — Clinical Overview
Drug Context
Zolpidem (Ambien, Ambien CR) is a non-benzodiazepine "Z-drug" sedative-hypnotic. It acts selectively at the GABA-A receptor benzodiazepine binding site (α-1 subunit). The 12.5 mg formulation is the controlled-release (CR) form — it has an immediate-release outer layer plus a slow-release inner layer, maintaining plasma concentrations longer than the immediate-release 10 mg tablet.
Total dose ingested: 112.5 mg (~9–11× the maximum therapeutic dose of 10–12.5 mg)
Expected Clinical Effects
| Feature | Details |
|---|---|
| Most common | Drowsiness, sedation, somnolence |
| CNS depression | Ataxia, hallucinations, slurred speech, confusion |
| Coma | Rare in isolated zolpidem overdose, even at 40× normal dose |
| Respiratory depression | Rare in isolation; significantly worsened by coingestants |
| Vomiting | Can occur at supratherapeutic doses (limits absorption) |
| Onset | Rapid — peak plasma levels within ~1–2 hours (CR may be delayed slightly) |
| Duration | Symptoms generally resolve within 8 hours |
Fatalities from isolated zolpidem overdose are rare. Most deaths involve coingestants — especially other sedative-hypnotics, alcohol, or antipsychotics.
Management
1. Supportive Care — mainstay of treatment
- Airway assessment and monitoring (position, O₂ saturation)
- Respiratory support if needed (intubation for airway protection if coingestants present or respiratory failure develops)
- IV access, vitals monitoring
- GCS monitoring
2. Decontamination
- Activated charcoal (1 g/kg) may be considered if the patient presents within 1–2 hours, airway is protected, and patient is cooperative
- Gastric lavage: not routinely indicated
3. Antidote — Flumazenil
- Flumazenil (benzodiazepine receptor antagonist) can reverse zolpidem sedation as it blocks the benzodiazepine-binding site on GABA-A
- However, routine use is NOT advised — risk of seizures (especially with mixed ingestions or benzodiazepine dependence), short half-life (re-sedation occurs), and may precipitate withdrawal
- Use is reserved for select cases (e.g., diagnostic, or brief reversal for airway management)
4. No role for:
- Hemodialysis or enhanced elimination
- Urinary alkalinization
Disposition
- Asymptomatic at 6 hours → can be medically cleared; refer for psychiatric evaluation if intentional ingestion
- Symptomatic → admit to monitored setting for respiratory monitoring
- Severe CNS/respiratory depression → ICU-level care
Key Red Flags to Rule Out
- Coingestants (alcohol, opioids, benzodiazepines, antipsychotics) — dramatically worsen prognosis
- Elderly patients — at greater risk for prolonged sedation
- Hepatic impairment — zolpidem undergoes hepatic metabolism to inactive metabolites; impairment prolongs effect
Sources: Rosen's Emergency Medicine, 9th ed.; Tintinalli's Emergency Medicine, 9th ed.
Bottom line: A 112.5 mg zolpidem CR ingestion is a significant overdose but is expected to cause primarily CNS sedation. Aggressive supportive care, airway monitoring, and careful exclusion of coingestants are the priorities. Prognosis is generally favorable with isolated zolpidem toxicity.
This is a shared conversation. Sign in to Orris to start your own chat.